The Impact of an SGLT2 Inhibitor versus Ursodeoxycholic Acid on Liver Steatosis in Diabetic Patients

The Impact of an SGLT2 Inhibitor versus Ursodeoxycholic Acid on Liver Steatosis in Diabetic Patients

Non-alcoholic fatty liver disease (NAFLD) is related to metabolic syndrome via insulin resistance, where preventing disease progression is crucial in the management process. The study included 240 NAFLD patients with type 2 diabetes who were randomly allocated into empagliflozin 25 mg (EMPA group),...

Full description

Bibliographic Details
Main Authors: Sahar H. Elhini, Engy A. Wahsh, Ahmed A. Elberry, Nadia F. El Ameen, Ahmed Abdelfadil Saedii, Shereen Mahmoud Refaie, Asmaa A. Elsayed, Hoda M. Rabea
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:Pharmaceuticals
Subjects:
ursodeoxycholic acid
empagliflozin
type 2 diabetes
NAFLD
MRI-PDFF
Online Access:https://www.mdpi.com/1424-8247/15/12/1516

Internet

https://www.mdpi.com/1424-8247/15/12/1516

Similar Items